Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Accumulated Expenses: 2023-2025

Historic Accumulated Expenses for Zenas BioPharma (ZBIO) over the last 1 years, with Sep 2025 value amounting to $45.4 million.

  • Zenas BioPharma's Accumulated Expenses rose 58.98% to $45.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.4 million, marking a year-over-year increase of 58.98%. This contributed to the annual value of $39.4 million for FY2024, which is 127.50% up from last year.
  • Zenas BioPharma's Accumulated Expenses amounted to $45.4 million in Q3 2025, which was up 1.88% from $44.5 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Accumulated Expenses ranged from a high of $45.4 million in Q3 2025 and a low of $17.3 million during Q4 2023.
  • For the 3-year period, Zenas BioPharma's Accumulated Expenses averaged around $33.9 million, with its median value being $34.0 million (2024).
  • Data for Zenas BioPharma's Accumulated Expenses shows a peak YoY skyrocketed of 127.50% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Zenas BioPharma's Accumulated Expenses stood at $17.3 million in 2023, then spiked by 127.50% to $39.4 million in 2024, then soared by 58.98% to $45.4 million in 2025.
  • Its last three reported values are $45.4 million in Q3 2025, $44.5 million for Q2 2025, and $28.2 million during Q1 2025.